Contact Information

Business Development

Collaborations and partnerships are core components of Kancera’s business model. Kancera’s strategy is to develop and commercialize its candidate drugs by partnering with other leading biotech and pharmaceutical companies that are focusing on inflammation and oncology in the specialty care setting.

Please contact CEO Peter Selin for any business development enquiries:


Kancera is publicly traded on the NASDAQ OMX First North Premier stock exchange. The company is developing a new class of drugs for treatment of inflammation and cancer.

The share is covered by Carlsquare, an independent equity research firm. Read Carlsquare’s most recent report here.

Investor relations and enquires from share holders are managed by Kancera’s Communications team. For any IR enquires please contact:


Public relations and enquires from media and news agencies are managed by Kancera’s Communications team. For any enquires please contact:

General enquiries

General enquires are managed by Kancera’s Communications team, please contact: